Brief: Abliva Drug Candidate NV354 Granted Orphan Drug Designation

Abliva AB

17/04/2023 09:57

April 17 (Reuters) - Abliva AB  ABLI.ST :
    * ABLIVA'S DRUG CANDIDATE NV354 GRANTED ORPHAN DRUG
DESIGNATION
FOR TREATMENT OF MITOCHONDRIAL DISEASE
    * DRUG CANDIDATE NV354 HAS BEEN GRANTED ORPHAN DRUG
DESIGNATION
(ODD) FOR TREATMENT OF MITOCHONDRIAL DISEASE BY UNITED STATES
FDA OFFICE OF ORPHAN PRODUCTS DEVELOPMENT

Source text for Eikon:  ID:nMFN57QGL9 
Further company coverage:  ABLI.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com;))